LV10183B - Oral composition for the treatment of inflammatory bowel diseases - Google Patents

Oral composition for the treatment of inflammatory bowel diseases Download PDF

Info

Publication number
LV10183B
LV10183B LVP-93-1026A LV931026A LV10183B LV 10183 B LV10183 B LV 10183B LV 931026 A LV931026 A LV 931026A LV 10183 B LV10183 B LV 10183B
Authority
LV
Latvia
Prior art keywords
epimer
butylidenedioxy
compound
dione
diene
Prior art date
Application number
LVP-93-1026A
Other languages
English (en)
Latvian (lv)
Other versions
LV10183A (lv
Inventor
Jan Ulimus
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10183(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Draco Ab filed Critical Draco Ab
Publication of LV10183A publication Critical patent/LV10183A/xx
Publication of LV10183B publication Critical patent/LV10183B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
LVP-93-1026A 1989-11-22 1993-08-10 Oral composition for the treatment of inflammatory bowel diseases LV10183B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8903914A SE8903914D0 (sv) 1989-11-22 1989-11-22 Oral composition for the treatment of inflammatory bowel diseases
PCT/SE1990/000738 WO1991007172A1 (en) 1989-11-22 1990-11-15 Oral composition for the treatment of inflammatory bowel diseases

Publications (2)

Publication Number Publication Date
LV10183A LV10183A (lv) 1994-10-20
LV10183B true LV10183B (en) 1995-08-20

Family

ID=20377544

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-1026A LV10183B (en) 1989-11-22 1993-08-10 Oral composition for the treatment of inflammatory bowel diseases

Country Status (36)

Country Link
US (1) US6423340B1 (es)
EP (1) EP0502092B1 (es)
JP (1) JP3145111B2 (es)
KR (1) KR0179042B1 (es)
AT (1) ATE125445T1 (es)
AU (1) AU643021B2 (es)
CA (1) CA2071518C (es)
DE (1) DE69021214T2 (es)
DK (1) DK0502092T3 (es)
EG (1) EG19642A (es)
ES (1) ES2074698T3 (es)
FI (2) FI104949B (es)
GR (1) GR3017691T3 (es)
HK (1) HK51897A (es)
HR (1) HRP920632B1 (es)
HU (2) HU216836B (es)
IE (1) IE74854B1 (es)
IL (1) IL96415A (es)
IS (1) IS1858B (es)
LT (1) LT3696B (es)
LV (1) LV10183B (es)
MY (1) MY104535A (es)
NO (1) NO304010B1 (es)
NZ (1) NZ235807A (es)
PL (1) PL166506B1 (es)
PT (1) PT95946A (es)
RU (1) RU2134104C1 (es)
SA (1) SA90110123B1 (es)
SE (1) SE8903914D0 (es)
SG (1) SG54210A1 (es)
SI (1) SI9012150A (es)
TW (1) TW250435B (es)
UA (1) UA37196C2 (es)
WO (1) WO1991007172A1 (es)
YU (1) YU48583B (es)
ZA (1) ZA908777B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
RU95115547A (ru) * 1993-01-08 1997-06-10 Астра Актиеболаг (SE) Стероидные соединения, способы их получения и фармацевтический препарат
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4332394A1 (de) * 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
WO1998022095A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6239120B1 (en) 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
SE9902673D0 (sv) * 1999-07-12 1999-07-12 Astra Ab New composition
ATE477804T1 (de) * 2001-03-15 2010-09-15 Soligenix Inc Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
WO2004052374A1 (en) 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
WO2004087109A1 (ja) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
ATE476185T1 (de) * 2003-09-15 2010-08-15 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
WO2005025578A1 (en) 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
WO2007056539A2 (en) * 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
AU2008230364A1 (en) * 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. Oral pharmaceutical preparation for colon-specific delivery
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
AU2009298139B2 (en) * 2008-10-03 2015-02-19 Dr. Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US8945615B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
AU2012211968A1 (en) * 2011-02-04 2013-08-29 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
MD480Z (en) * 2011-07-07 2012-09-30 Elvira Andon Method for treating acute ulcerative nonspecific colitis
JOP20200144A1 (ar) 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
KR102174942B1 (ko) 2013-10-29 2020-11-06 틸로츠 파마 아게 지연 방출 약물 제형
RU2018111690A (ru) * 2015-09-11 2019-10-11 Сан Фармасьютикл Индастриз Лтд. Пероральная лекарственная форма будесонида
CN105663091A (zh) * 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
CA3011565C (en) * 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750937C2 (ru) * 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996356A (en) 1969-07-02 1976-12-07 Hoffmann-La Roche Inc. Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
SE7813246L (sv) 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8008524L (sv) 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE8306370D0 (sv) 1983-11-18 1983-11-18 Draco Ab Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions
US4708867A (en) 1983-12-19 1987-11-24 Key Pharmaceuticals, Inc. Minipellets
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
DE3536267A1 (de) 1985-10-11 1987-04-16 Bayer Ag Azofarbstoffe sowie fluessigkristallines material enthaltend azofarbstoffe
SE8506015D0 (sv) 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE10307386A1 (de) 2003-02-21 2004-09-09 Dieter Wildfang Gmbh Verfahren zum außenseitigen Beschichten eines sanitären Auslaufteiles sowie sanitäres Auslaufteil

Also Published As

Publication number Publication date
HU216836B (hu) 1999-09-28
CA2071518A1 (en) 1991-05-23
EP0502092A1 (en) 1992-09-09
IL96415A (en) 1995-11-27
PL166506B1 (pl) 1995-05-31
EG19642A (en) 1995-08-30
IE74854B1 (en) 1997-08-13
SI9012150A (sl) 1998-08-31
IS3644A7 (is) 1991-05-23
US6423340B1 (en) 2002-07-23
RU2134104C1 (ru) 1999-08-10
DE69021214T2 (de) 1996-01-04
YU215090A (sr) 1996-01-09
ATE125445T1 (de) 1995-08-15
CA2071518C (en) 2002-11-12
ES2074698T3 (es) 1995-09-16
SG54210A1 (en) 1998-11-16
SA90110123B1 (ar) 1999-06-06
ZA908777B (en) 1991-07-31
IE904170A1 (en) 1991-05-22
NZ235807A (en) 1993-02-25
HRP920632B1 (en) 1999-10-31
HUT60630A (en) 1992-10-28
FI922325A0 (fi) 1992-05-21
NO922004D0 (no) 1992-05-21
KR920703025A (ko) 1992-12-17
NO304010B1 (no) 1998-10-12
YU48583B (sh) 1998-12-23
PL287844A1 (en) 1991-12-02
FI19991893A (fi) 1999-09-06
MY104535A (en) 1994-04-30
SE8903914D0 (sv) 1989-11-22
LV10183A (lv) 1994-10-20
JP3145111B2 (ja) 2001-03-12
TW250435B (es) 1995-07-01
NO922004L (no) 1992-05-21
IL96415A0 (en) 1991-08-16
FI104949B (fi) 2000-05-15
HK51897A (en) 1997-05-02
AU643021B2 (en) 1993-11-04
JPH05501705A (ja) 1993-04-02
HU9201700D0 (en) 1992-08-28
KR0179042B1 (ko) 1999-03-20
UA37196C2 (uk) 2001-05-15
LT3696B (en) 1996-02-26
LTIP1751A (en) 1995-07-25
IS1858B (is) 2003-03-27
DK0502092T3 (da) 1995-12-27
FI922325A (fi) 1992-05-21
PT95946A (pt) 1991-09-13
AU7786491A (en) 1991-06-13
EP0502092B1 (en) 1995-07-26
GR3017691T3 (en) 1996-01-31
HRP920632A2 (en) 1995-04-30
DE69021214D1 (de) 1995-08-31
WO1991007172A1 (en) 1991-05-30

Similar Documents

Publication Publication Date Title
US5643602A (en) Oral composition for the treatment of inflammatory bowel disease
AU643021B2 (en) Oral composition for the treatment of inflammatory bowel diseases
RU2435568C2 (ru) Таблетки с высвобождением активного ингредиента, происходящим в определенном месте и в определенное время
CA1302262C (en) Pharmaceutical composition containing flutiasone propionate
EP0040590A2 (en) A pharmaceutical preparation having improved release properties
WO1995006464A1 (de) Pharmazeutische präparate zur gezielten behandlung von morbus crohn und colitis ulcerosa
CA2579732C (en) Tablets with site time-controlled gastrointestinal release of active ingredient
EP1315481A1 (de) Arzneimittel zur behandlung von darmerkrankungen
JP3469926B2 (ja) 大腸内放出型医薬製剤用粒状物
AU627335B2 (en) Aspirin granules with gastroprotectant coating
JP5371189B2 (ja) 炎症性腸疾患の治療のためのシクレソニドの使用
EP1100481B1 (en) Pharmaceutical formulations comprising beclomethasone dipropionate for the treatment of inflammatory bowel disease
AU2011232809B2 (en) Tablets with site and time-controlled gastrointestinal release of active ingredient
WO1994007503A1 (en) Enteric preparations